RXi Pharmaceuticals this week reported a sharp drop in its second-quarter losses as it reduced research and development spending.

The company's net loss in the quarter fell to $2.1 million, or $0.12 per share, from a year-ago loss of $5 million, or $0.37 per share.

R&D expenses shrank to $2.3 million from $3 million, while general and administrative costs edged up to $2.5 million from $2 million in the second quarter last year.

As of June 30, RXi had cash, cash equivalents, and short-term investments totaling $11.1 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.